STADA Arzneimittel AG
STADA Arzneimittel AG is a German pharmaceutical company founded in 1895 that develops, manufactures, and distributes Consumer Healthcare products, generics, and specialty pharmaceuticals including biosimilars across 100+ countries. It serves patients, pharmacists, and healthcare systems, generating €4.3 billion in FY2025 revenue.
- Company typePrivate
- Founded1895
- HeadquartersBad Vilbel, Germany
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What STADA Arzneimittel AG does
STADA Arzneimittel AG is a German-headquartered, privately-held pharmaceutical company operating across three pillars: Consumer Healthcare, Generics, and Specialty Pharmaceuticals. Founded in 1895 as a pharmacists' cooperative and headquartered in Bad Vilbel, Germany, the company manufactures and distributes branded over-the-counter products (Nizoral, Grippostad, Zoflora, Silomat, Hirudoid, Lunestil), affordable generic medicines (where it ranks fourth in Europe by sales), and a growing biosimilars portfolio (adalimumab, ustekinumab, golimumab/Gotenfia, bevacizumab, pegfilgrastim, teriparatide, ranibizumab, epoetin zeta, denosumab) developed with partners including Alvotech, Bio-Thera, Xbrane, and CuraTeQ. Specialty Pharmaceuticals surpassed €1 billion in revenue in 2025 with 17% YoY growth, led by orphan drug Kinpeygo for IgA nephropathy and biosimilar Uzpruvo.
The company sells in over 100 countries through wholly-owned subsidiaries, pharmacy distribution networks, and channel partnerships (notably Sanofi for 20 European and 10 Eurasian countries). It employs 11,749 people worldwide and reported FY2025 adjusted revenues of €4.3 billion with adjusted EBITDA of €961 million. The business model relies on branded and generic pharmaceutical sales, licensing/distribution fees, and royalty income from in- and out-licensed products.
In March 2026, CapVest Partners LLP completed a €10 billion majority acquisition, returning STADA to private ownership under a sponsor with stated intent to accelerate growth via M&A. Subsequent deals include the €85 million Saudi Arabia manufacturing hub (February 2026), Locobase derma line acquisition (May 2026), and the Orifarm VMS portfolio acquisition of 16 brands (June 2026). The company also deploys an AI-powered Lean Auditing system that reduces supplier audit reporting time by 40%, saving more than 11,000 hours annually.
STADA Arzneimittel AG firmographics
Firmographics- Name
- STADA Arzneimittel AG
- Legal name
- STADA Arzneimittel AG
- Website
- https://stada.com
- Company type
- Private
- Founded year
- 1895
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- STADA Arzneimittel AG is a German pharmaceutical company founded in 1895 that develops, manufactures, and distributes Consumer Healthcare products, generics, and specialty pharmaceuticals including biosimilars across 100+ countries. It serves patients, pharmacists, and healthcare systems, generating €4.3 billion in FY2025 revenue.
- Ownership category
- akta.pro rank
STADA Arzneimittel AG industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where STADA Arzneimittel AG is headquartered
LocationHeadquarters
- HQ city
- Bad Vilbel
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
STADA Arzneimittel AG business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceuticals: STADA's generic drugs business is the backbone of the company since 1895. As the fourth-largest generics manufacturer and supplier in Europe by sales, STADA provides affordable versions of branded medications, with seven out of ten medicines prescribed in Europe being generics accounting for about 30% of pharmaceutical expenditure.
- Consumer Healthcare Products: OTC products including Nizoral (dandruff/scalp care), Grippostad (cough/cold), Zoflora (disinfectants), Silomat (cough relief), Hirudoid (pain relief), Lunestil (sleep), and vitamins/minerals/gastro products sold through pharmacies and retail.
- Specialty Pharmaceuticals: High-value innovative medicines for chronic, severe, or rare diseases including biosimilars (adalimumab, ustekinumab, golimumab, bevacizumab, pegfilgrastim, teriparatide, ranibizumab), oncology products, and orphan drugs. The specialty segment surpassed €1 billion in revenue in 2025 with 17% growth.
- Licensing and Distribution Agreements: STADA generates revenue through in-licensing and out-licensing arrangements, including partnerships with Bio-Thera (Gotenfia), Alvotech (biosimilars), and distribution agreements with Sanofi, covering various geographies including Europe and emerging markets.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels9 records
STADA Arzneimittel AG product offering
Product offeringCore offering
STADA Arzneimittel AG manufactures, markets, and distributes a diversified pharmaceutical portfolio across three pillars: Consumer Healthcare (OTC brands such as Nizoral, Grippostad, Zoflora, Silomat, Hirudoid, Lunestil), Generics (affordable off-patent medicines as Europe's fourth-largest generics manufacturer), and Specialty Pharmaceuticals (biosimilars and innovative treatments for oncology, immunology, nephrology, ophthalmology, bone health, and neurology). Products are sold in over 100 countries through pharmacy networks, retail channels, e-commerce, and distribution partnerships with major pharma companies including Sanofi, Alvotech, Bio-Thera, and Xbrane.
Product overview
STADA Arzneimittel AG is a leading global healthcare and pharmaceuticals company with a three-pillar strategy spanning Consumer Healthcare products, Generics, and Specialty Pharmaceuticals. The company operates in over 100 countries with approximately 11,749 employees, achieving adjusted group revenues of EUR 4.3 billion and adjusted EBITDA of EUR 961 million in financial year 2025. The Consumer Healthcare portfolio includes major brands such as Nizoral (anti-dandruff/scalp care), Grippostad (cold/flu), Zoflora (disinfectants), Snup (nasal spray), Silomat (cough relief), Lunestil (sleep aids), and acquired brands including Nycoplus, Apovit, and Vitrum (VMS). The Specialty Pharmaceuticals segment offers innovative treatments and biosimilars within therapeutic areas including oncology (bevacizumab, pegfilgrastim), nephrology (Kinpeygo for IgA nephropathy, epoetin zeta), neurology (Parkinson's combination therapies), immunology (adalimumab, ustekinumab biosimilars), bone health (teriparatide), and ophthalmology (ranibizumab). The Generics segment provides affordable medications as the fourth-largest generics supplier in Europe. Recent strategic acquisitions include the Orifarm VMS portfolio and Locobase derma line, with partnerships spanning Alvotech, Bio-Thera, Xbrane, CuraTeQ, and others.
Differentiator
Problem solved
Functional benefit
Brands
- Nizoral: Medical treatment against dandruff; anti-dandruff brand in EMEA markets
- Grippostad
- Zoflora
- Silomat
- Hirudoid
- Lunestil
- SNUP
- Covonia
- Synthol
- Cetebe
- Orofar
- Oilatum
- BIOPRON
- Kinpeygo
- Uzpruvo
- Gotenfia
- Movymia
Products and services
- Nizoral Medical treatment against dandruff with clinically proven efficacy and long-lasting relapse prevention for scalp care, sold through European pharmacies.
- Grippostad Medicine against flu infections and colds, sold through pharmacies.
- Zoflora Disinfectant to keep households clean from harmful bacteria.
- Snup Nasal spray medicine for decongestion of colds.
- Silomat Relief of irritating, dry coughs.
- Hirudoid Topical treatment for venous insufficiency and phlebology, joint and muscular pain.
- Lunestil Sleeping pills for short-term treatment of acute sleep disorders.
- Covonia Cough and cold remedy brand.
- Synthol Pain relief product.
- Cetebe Vitamins and minerals supplement for gastrointestinal health.
- Oilatum Dermatology product for skincare including cracked, dry and eczema-prone skin.
- BIOPRON Premium probiotics and vitamins/minerals/gastro supplements.
- ColdZyme Oral spray medical device for cold and flu symptoms, distributed by STADA in Germany and Austria under partnership with Enzymatica.
- Nycoplus Market-leading pharmacy vitamins, minerals and supplements (VMS) line in Norway, acquired from Orifarm.
- Apovit Market-leading VMS range in Danish pharmacies, acquired from Orifarm.
- Vitrum Broad VMS brand in Poland, acquired from Orifarm.
- Locobase Derma Line Dermatology product line in the Nordics, acquired to strengthen consumer healthcare leadership in Europe.
- Kinpeygo Innovative targeted-release formulation of budesonide for treatment of primary immunoglobulin A nephropathy (IgAN), a rare kidney disease. First medicine approved in EU for this indication.
- Uzpruvo (Ustekinumab Biosimilar) Ustekinumab biosimilar, Europe's first ustekinumab biosimilar, for autoimmune diseases with continued double-digit expansion across more than 20 markets.
- Adalimumab Biosimilar High-concentration adalimumab biosimilar for autoimmune diseases including rheumatoid arthritis and psoriasis, available in Europe.
- Bevacizumab Biosimilar Biosimilar for cancer treatment, launched with focus on Europe and available in Germany and Netherlands with expansion to other European countries.
- Pegfilgrastim Biosimilar Biosimilar for cancer patients with neutropenia.
- Movymia (Teriparatide Biosimilar) Biosimilar teriparatide for treatment of osteoporosis, launched in 24 countries in partnership with Richter-Helm.
- Ranibizumab Biosimilar Biologic ophthalmic medicine for ophthalmologic conditions, launched in Europe in partnership with Xbrane.
- Gotenfia (Golimumab Biosimilar) Golimumab biosimilar referencing Johnson & Johnson's Simponi, approved for chronic inflammatory autoimmune diseases including rheumatoid arthritis and ulcerative colitis.
- AVT03 (Denosumab Biosimilar) Biosimilar to Prolia and Xgeva (denosumab) for osteoporosis and oncology treatments, marketed through partnerships with STADA and Dr. Reddy's.
- Bortezomib STADA Anti-cancer drug launched in 14 European countries as first generic and innovative ready-to-use injection solution.
- STADA Generics Affordable generic pharmaceutical products containing the exact active pharmaceutical ingredient as original patented products at substantially lower prices; STADA is the fourth-largest manufacturer and supplier of generics in Europe.
- Levodopa-Carbidopa-Entacapone Combination (Parkinson's) Device-driven combination for late-stage Parkinson's disease therapy, including new triple combination product with modern pump technology.
Quantifiable outcome
- STADA doubled e-commerce sales between 2022 and 2025
- +4 more outcomes
Companies that use STADA Arzneimittel AG
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
STADA Arzneimittel AG technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
STADA Arzneimittel AG partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major and core.
- Enzymatica ABmajorSwedish life science company Enzymatica AB partnered with STADA for the launch and distribution of Enzymatica's ColdZyme oral spray medical device in Germany and Austria. STADA markets the product under its own brand names through its established commercial platform, with commercial impact expected from the 2026/2027 cold and flu season.
- CuraTeQ Biologics (Aurobindo Pharma)coreAurobindo Pharma's biosimilars arm CuraTeQ Biologics partnered with STADA to market and distribute two EMA-approved biosimilars (for neutropenia) in select EU territories including France and Germany under new brand names. The partnership aims to expand CuraTeQ's market presence in Europe.
- Bio-Thera SolutionscoreSTADA and Bio-Thera received European Commission marketing authorization for Gotenfia (golimumab), a biosimilar to Johnson & Johnson's Simponi, approved for multiple chronic inflammatory autoimmune diseases. Bio-Thera developed and manufactures the product while STADA holds exclusive rights to commercialize it across the EU, UK, Switzerland and selected other countries. Gotenfia was the second golimumab biosimilar approved in the EU. Bio-Thera previously granted STADA exclusive commercialization rights in a deal worth up to USD 157.5 million plus royalties.
- XbranemajorPartnership with Sweden's Xbrane to bring the biologic ophthalmic medicine ranibizumab to patients in Europe, supporting patient access to eye disease treatments.
- AdalvomajorExtension of a strategic partnership with Adalvo to obtain commercial rights in Europe to five additional active ingredients in therapeutic categories including oncology and diabetes.
- AlvotechcoreStrategic partnership with Iceland's Alvotech to expand patient access to adalimumab biosimilar (for autoimmune conditions) in Europe, and to submit marketing authorization for ustekinumab biosimilar (AVT04, proposed biosimilar to Stelara). Also partnered with Alvotech for AVT03 (denosumab biosimilar, Prolia/Xgeva) commercialized in Europe.
- Calliditas Therapeutics ABcoreSTADA partnered with Sweden's Calliditas to obtain the first approval in the EU for a treatment for the rare kidney disease immunoglobulin A nephropathy (IgAN). STADA commercializes Kinpeygo (targeted-release budesonide) for this indication in Europe. In 2026, STADA hosted a symposium on IgA nephropathy at ERA 2026 with over 1,350 participants.
- SanoficoreSTADA acquired 16 well-established consumer healthcare brands from Sanofi and entered a distribution agreement to market and distribute Sanofi's entire consumer healthcare portfolio in 20 European countries and 10 Eurasian countries. This partnership strengthened STADA's position as a leading Consumer Healthcare company in Europe.
- mAbxiencemajorSTADA partnered with mAbxience to expand its specialty oncology portfolio with the launch of biosimilar bevacizumab, available to oncologists and their patients in Germany and the Netherlands with launches in other European countries following.
- Richter-Helm BioTecmajorSTADA collaborates with Richter-Helm-BioTec GmbH & Co.KG on the in-licensing of teriparatide for the treatment of osteoporosis, expanding its biosimilar portfolio. Movymia (teriparatide biosimilar) was launched in 24 countries.
- GlaxoSmithKline (GSK)coreSTADA acquired 15 well-established consumer healthcare brands from GSK across more than 40 countries, following a previous deal for five non-prescription skincare brands. This transaction made STADA a major Consumer Healthcare player.
Scale indicators13 records
Recent moves8 records
Expansion highlights6 records
STADA Arzneimittel AG competitors and assessment
Company assessmentDirect peers
- Sandoz: Sandoz, spun out of Novartis in 2023, is the world's largest generics and biosimilars company with a comparable European footprint and biosimilar pipeline (hyrimoz, eculizumab, Omnitrope) that competes head-to-head with STADA's adalimumab, pegfilgrastim, and other biosimilars in EU tenders.
- Teva Pharmaceutical Industries: Teva is the largest global generics manufacturer with a broad European generics portfolio, OTC brands, and a biosimilar pipeline (Truxima, Herzuma), overlapping directly with STADA's three-pillar generics/CHC/specialty model across Germany, Eastern Europe, and Eurasia.
- Viatris: Viatris (Mylan-Upjohn combination) is a top-three global generics player with significant European presence across retail generics, biosimilars, and branded complex generics, directly comparable to STADA's generics and specialty portfolio and competitive in the same tender markets.
- KRKA: KRKA is a Slovenia-based generics manufacturer with strong Central and Eastern European market positions and an expanding consumer healthcare and biosimilar footprint, making it a close geographic and portfolio peer to STADA in CEE markets like Poland, Czechia, and the Balkans.
- Hikma Pharmaceuticals: Hikma is a UK-listed generics and specialty manufacturer with significant operations across Europe, the Middle East, and North America; its branded generics, injectables, and biosimilar pipeline closely parallel STADA's specialty and generics strategy and overlap in MENA and European markets.
- Polpharma Group: Polpharma is one of the largest pharmaceutical manufacturers in Central and Eastern Europe with a generics-led portfolio and growing OTC presence, making it a regional direct competitor to STADA in Poland, Russia, and CIS markets.
Emerging players
- Alvotech: Alvotech is a pure-play biosimilar developer partnering with STADA on adalimumab (high-concentration), ustekinumab (AVT04), and denosumab (AVT03); while a partner today, it competes with STADA in tenders and represents a hybrid peer-and-supplier relationship for biosimilars.
- Bio-Thera Solutions: Bio-Thera is a Chinese biosimilar developer that partnered with STADA for Gotenfia (golimumab) commercialization in EU/UK/Switzerland; it is a current partner but competes in the broader biosimilar development landscape and signals emerging Asia-based competition for STADA's specialty pipeline.
Broad incumbents
- Perrigo Company: Perrigo is a global OTC consumer healthcare leader with a European store-brand and self-care portfolio that overlaps directly with STADA's CHC brands (Nizoral, Grippostad, Zoflora) in European pharmacy and retail channels.
- Bayer Consumer Health: Bayer's Consumer Health division is a global OTC powerhouse with leading European brands across cough/cold, dermatology, and pain — competing with STADA's Grippostad, Silomat, Hirudoid, and Oilatum in the same European pharmacy shelves.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
STADA Arzneimittel AG social profiles
Digital presenceSTADA Arzneimittel AG compliance and trust
Trust signalCompliance6 records
STADA Arzneimittel AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
STADA Arzneimittel AG leadership team
Management profileNumber of profiles
Profiles11 records
STADA Arzneimittel AG subsidiaries and ownership
Company hierarchySubsidiaries16 records
STADA Arzneimittel AG funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
STADA Arzneimittel AG M&A and investment
M&A and investmentM&A10 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about STADA Arzneimittel AG
What does STADA Arzneimittel AG do?
STADA Arzneimittel AG manufactures, markets, and distributes a diversified pharmaceutical portfolio across three pillars: Consumer Healthcare (OTC brands such as Nizoral, Grippostad, Zoflora, Silomat, Hirudoid, Lunestil), Generics (affordable off-patent medicines as Europe's fourth-largest generics manufacturer), and Specialty Pharmaceuticals (biosimilars and innovative treatments for oncology, immunology, nephrology, ophthalmology, bone health, and neurology). Products are sold in over 100 countries through pharmacy networks, retail channels, e-commerce, and distribution partnerships with major pharma companies including Sanofi, Alvotech, Bio-Thera, and Xbrane.
Is STADA Arzneimittel AG a public or private company?
STADA Arzneimittel AG is a private company. It is classified as private equity controlled and is currently operating.
When was STADA Arzneimittel AG founded?
STADA Arzneimittel AG was founded in 1895. It employs 5,001 to 10,000 people.
Where is STADA Arzneimittel AG based?
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany, in the Europe region.
How does STADA Arzneimittel AG make money?
Four revenue lines are on record. Generic Pharmaceuticals are the primary driver. The others are consumer Healthcare Products, specialty Pharmaceuticals and licensing and Distribution Agreements.
Who are STADA Arzneimittel AG's main competitors?
Direct peers on record are Sandoz, Teva Pharmaceutical Industries, Viatris, KRKA, Hikma Pharmaceuticals and Polpharma Group. Emerging players are Alvotech and Bio-Thera Solutions. Broad incumbents are Perrigo Company and Bayer Consumer Health.
Does STADA Arzneimittel AG have an API?
No public API is recorded for STADA Arzneimittel AG.
What industry is STADA Arzneimittel AG in?
STADA Arzneimittel AG's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.